[{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Bios Partners","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2020","type":"Series B Financing","leadProduct":"ONL1204","moa":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"ONL Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0.050000000000000003,"dosageForm":"Intravitreal Injection","sponsorNew":"ONL Therapeutics \/ Bios Partners","highestDevelopmentStatusID":"6","companyTruncated":"ONL Therapeutics \/ Bios Partners"},{"orgOrder":0,"company":"AmbioPharm","sponsor":"ONL Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"ONL1204","moa":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"AmbioPharm","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AmbioPharm \/ ONL Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"AmbioPharm \/ ONL Therapeutics"},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"ONL1204","moa":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"ONL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ONL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ONL Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"ONL1204","moa":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"ONL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ONL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ONL Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"ONL1204","moa":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"ONL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ONL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ONL Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Bios Partners","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Series C Financing","leadProduct":"ONL1204","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ONL Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.02,"dosageForm":"Solution","sponsorNew":"ONL Therapeutics \/ Bios Partners","highestDevelopmentStatusID":"8","companyTruncated":"ONL Therapeutics \/ Bios Partners"},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"ONL1204","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ONL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ONL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ONL Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"ONL1204","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ONL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ONL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ONL Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2024","type":"Series D Financing","leadProduct":"ONL1204","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ONL Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ONL Therapeutics \/ Johnson & Johnson","highestDevelopmentStatusID":"14","companyTruncated":"ONL Therapeutics \/ Johnson & Johnson"}]

Find Clinical Drug Pipeline Developments & Deals for ONL1204

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The funds will advance the development of ONL1204 Ophthalmic Solution by initiating a Phase 2 global study for treating GA associated with dry age-related macular degeneration.

                          Brand Name : ONL1204

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          September 13, 2024

                          Lead Product(s) : ONL1204

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase I

                          Sponsor : Johnson & Johnson

                          Deal Size : $65.0 million

                          Deal Type : Series D Financing

                          blank

                          02

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : ONL1204 is a novel, first-in-class small molecule Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs across a range of retinal diseases and conditions.

                          Brand Name : ONL1204

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 28, 2023

                          Lead Product(s) : ONL1204

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : ONL1204 is a novel, Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs across a range of retinal diseases and conditions. It is being investigated in patients with macula-off rhegmatogenous retinal ...

                          Brand Name : ONL1204

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 12, 2023

                          Lead Product(s) : ONL1204

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Proceeds from the financing will primarily support the advancement of ONL1204 Ophthalmic Solution, a novel, first-in-class small molecule Fas inhibitor, into a Phase 2 clinical trial in patients with macula-off rhegmatogenous retinal detachment (RRD).

                          Brand Name : ONL1204

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          March 08, 2023

                          Lead Product(s) : ONL1204

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : Bios Partners

                          Deal Size : $15.0 million

                          Deal Type : Series C Financing

                          blank

                          05

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : ONL1204 is a novel, first-in-class small molecule Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs across a range of retinal diseases and conditions.

                          Brand Name : ONL1204

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          February 13, 2023

                          Lead Product(s) : ONL1204

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : ONL1204 is a novel, first-in-class small molecule Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs across a range of retinal diseases and conditions.

                          Brand Name : ONL1204

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          February 01, 2023

                          Lead Product(s) : ONL1204

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : ONL1204 is a novel, first-in-class small molecule Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs across a range of retinal diseases and conditions.

                          Brand Name : ONL1204

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 26, 2023

                          Lead Product(s) : ONL1204

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : ONL1204 Ophthalmic Solution is a novel, first-in-class small peptide Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs in a range of retinal diseases and conditions.

                          Brand Name : ONL1204

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 12, 2022

                          Lead Product(s) : ONL1204

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : IND Enabling

                          Sponsor : ONL Therapeutics

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : This funding supports the completion of a Phase 1 study in retinal detachment with ONL’s lead compound ONL1204. In addition, the funding will advance ONL1204 in two chronic indications, glaucoma and dry age-related macular degeneration.

                          Brand Name : ONL1204

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          December 22, 2020

                          Lead Product(s) : ONL1204

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase I

                          Sponsor : Bios Partners

                          Deal Size : $46.9 million

                          Deal Type : Series B Financing

                          blank